What Is A CBG?

What a CBG Actually Is

A CBG is a specialist in Clinical Biochemical Genetics: the discipline that diagnoses and interprets inherited metabolic disease through the chemistry of the body. Where a molecular geneticist reads DNA, a biochemical geneticist reads the downstream consequences of a broken enzyme, transporter or cofactor pathway. The raw material is plasma amino acids, urine organic acids, acylcarnitine profiles, enzyme assays, and the clinical picture that ties them together.

The work sits at an unusual intersection. A newborn screen flags an elevated C5-OH acylcarnitine, and someone has to decide whether that reflects 3-MCC deficiency, a maternal condition, or something else entirely. A child presents with hypoglycemia and hepatomegaly, and the differential runs through glycogen storage disease, fructose-1,6-bisphosphatase deficiency and fatty acid oxidation defects. The CBG is the person who reasons from the metabolite pattern back to the broken step, then recommends confirmatory testing and management.

If you have seen this acronym elsewhere and wondered how it fits, the short version is that this site uses CBG exclusively for Clinical Biochemical Genetics. For a quick orientation on the terminology itself, see our explainers on what CBG stands for and CBG meaning.

Who Certifies It and Where the Blueprint Lives

Certification is issued by the American Board of Medical Genetics and Genomics (ABMGG). The ABMGG publishes content outlines and blueprints for its specialties on its initial-certification pages, and the document that governs this credential is the ABMGG Biochemical Genetics Blueprint and Content Codes, effective August 2025. That blueprint is the single most important primary source a candidate can read, because it names exactly which topics are fair game.

Treat the blueprint as a map of exam objectives, not a complete curriculum. It tells you what is tested; it does not teach you the biochemistry. Strong candidates pair it with textbooks, case-based literature and, where available, hands-on exposure in a clinical laboratory. For the full eligibility picture, read our guide to CBG requirements and prerequisites.

How the Blueprint Divides the Content

The blueprint organizes the exam into fifteen content categories, each with an approximate percentage. Here they are exactly as published:

These percentages total 102% as published, a discrepancy in the source that we have preserved rather than adjusted. Read them as relative emphasis, not as a precise question count. For a category-by-category walkthrough, see CBG Exam Domains: Complete Guide to All 15 Content Areas.

The Disorder Families You Must Master

The top four categories (Amino acids, Lipids, Organic acids and Lysosomes) account for roughly half the blueprint. Depth here pays off disproportionately.

Amino acids: the largest single domain

Organic acids and the acylcarnitine connection

Organic acid disorders reward pattern recognition. The blueprint groups methylmalonic acidemia (excluding cobalamin defects) with propionic acidemia, then separates C5-related conditions, including IVA, from C5-OH-related conditions such as 3-MCC deficiency. It also names glutaric acidemia type I, ketone body disorders (HMG-CoA lyase, SCOT), and a catch-all that includes glutathione synthetase deficiency, ECHS1 deficiency and non-type 1 3-methylglutaconic aciduria.

Lipids: fatty acid oxidation and cholesterol

Fatty acid oxidation disorders span short-, medium- and long-chain defects and multiple acyl-CoA dehydrogenase deficiency (GA2). The same category covers hyperlipidemias, including Tangier disease, and disorders of cholesterol metabolism such as Smith-Lemli-Opitz syndrome, Niemann-Pick C and bile acid disorders. That mix of acylcarnitine interpretation and sterol biochemistry makes Lipids a domain where two quite different skill sets meet.

Lysosomes: enzyme names and substrate logic

The lysosomal domain lists the mucopolysaccharidoses by type (I, II, III, IV, VI and VII), the sphingolipidoses (Gaucher, Fabry, GM2 gangliosidoses including Tay-Sachs and Sandhoff, Krabbe, Niemann-Pick A and B, GM1 gangliosidosis), multiple enzyme deficiencies including ML-II and ML-III and multiple sulfatase deficiency, and a final group featuring Pompe disease, cystinosis and NCL. Build a table linking each disorder to its deficient enzyme, accumulating substrate and typical screening approach.

The mid-weight domains

Carbohydrates (10%) covers glycogenoses (with GSD II handled under lysosomes), glycolysis and gluconeogenesis disorders, galactose and fructose metabolism, congenital disorders of glycosylation, and pentose phosphate pathway conditions. Cofactors (7%) and Mitochondria (7%) are individually modest, but they interlock with the larger domains: a pyridoxine- or biotin-responsive presentation, for instance, can surface in an amino acid or organic acid scenario.

The Laboratory Domain: Small Weight, Big Consequence

At about 8%, the Laboratory category outweighs Peroxisomes, Purines and pyrimidines, Transport, Metals and Neurotransmitters individually, and it exceeds several of them combined. It covers quality assurance and quality control, artifact recognition, analytical techniques, and regulations.

This is the domain where clinical reasoning meets bench reality. Artifact recognition is a good example: an unusual peak in an organic acid profile may reflect medication, diet, specimen handling or contamination rather than disease, and a competent CBG must know the difference. Candidates who come from purely clinical backgrounds sometimes underweight this section; those from analytical backgrounds sometimes underweight the disease content. Know which camp you are in and compensate.

Where CBGs Work and Who Hires Them

Biochemical geneticists typically practice in settings where inherited metabolic disease is diagnosed and managed. Common environments include:

• Academic medical centers and children's hospitals: metabolic clinics that combine patient care with diagnostic interpretation.
• Clinical biochemical genetics laboratories: hospital-based or reference laboratories running amino acid, organic acid, acylcarnitine and enzyme testing.
• Newborn screening programs: public health and affiliated laboratories that follow up abnormal screens.
• Industry and research: diagnostic developers and therapeutic programs targeting rare metabolic disease.

Compensation varies widely by setting, role and region, and we avoid quoting unsourced figures. For a grounded discussion, see our CBG salary guide, our analysis of whether the certification is worth it, and the overview of CBG jobs.

Exam Timing and Scheduling Mechanics

Two scheduling facts matter most. First, the biochemical specialties are offered in odd years. Second, the next CBG exam is identified as August 2027. The ABMGG has also announced a transition to an annual certifying examination schedule and has published news about the 2027 certification exams, scheduled for August 11 to 14, 2027, so candidates should monitor the Board's announcements for the final dates and any changes to cadence.

We deliberately do not quote an exam fee, time limit, question count or passing score here, because those details were not confirmed in the official blueprint materials. Verify them directly with the ABMGG before budgeting or planning. Our pages on certification cost, passing score and exam dates track what can and cannot be confirmed.

Sequencing Your Preparation Around the Blueprint

The one place a schedule helps is in ordering domains by weight and by dependency. Because several categories share underlying biochemistry, studying them in a deliberate sequence reduces re-learning. Here is one logical ordering, adaptable to your own timeline:

For a fuller plan, see the CBG study guide and the one-page CBG cheat sheet. When you are ready to test recall under realistic conditions, try the practice questions on our main practice test site, and consult our difficulty guide and pass rate discussion to calibrate your expectations.

Frequently Asked Questions